MRD detection in multiple myeloma: Comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods Journal Article


Authors: Roshal, M.; Flores-Montero, J. A.; Gao, Q.; Koeber, M.; Wardrope, J.; Durie, B. G. M.; Dogan, A.; Orfao, A.; Landgren, O.
Article Title: MRD detection in multiple myeloma: Comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods
Abstract: In patients with multiple myeloma, obtaining posttreatment minimal residual disease (MRD) negativity is associated with longer progression-free survival and overall survival. Here, we compared the diagnostic performance of a single 10-color tube with that of a EuroFlow 8-color 2-tube panel forMRDtesting. Bone marrow samples from 41 multiple myeloma patients were tested in parallel using the 2 approaches. Compared with the sum of the cells from the EuroFlow two 8-color tubes, the Memorial Sloan Kettering Cancer Center (MSKCC) single 10color tube had a slight reduction in total cell number with a mean ratio of 0.85 (range, 0.571.46; P < .05), likely attributable to permeabilization of the cells. Percent of plasma cells showed a high degree of concordance (r(2) = 0.97) as did normal plasma cells (r(2) = 0.96), consistent with no selective plasma cell loss. Importantly, concordant measurement of residual disease burden was seen with abnormal plasma cells (r(2) = 0.97). The overall concordance between the 2 tests was 98%. In 1 case, there was a discrepancy near the limit of detection of both tests in favor of the slightly greater theoretical sensitivity of the EuroFlow 8-color 2-tube panel (analytical sensitivity limit of MSKCC single 10-color tube: 6 cells in 1 million with at least 3 million cell acquisitions; EuroFlow 8-color 2-tube panel: 2 cells in 1 million with the recommended 10 million cell acquisitions).
Keywords: minimal residual disease; myeloma; impact; plasma-cell; multiparameter flow-cytometry
Journal Title: Blood Advances
Volume: 1
Issue: 12
ISSN: 2473-9529
Publisher: American Society of Hematology  
Date Published: 2017-05-09
Start Page: 728
End Page: 732
Language: English
ACCESSION: WOS:000400980900003
DOI: 10.1182/bloodadvances.2016003715
PROVIDER: wos
PMCID: PMC5728052
PUBMED: 29296716
Notes: Article -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Ahmet Dogan
    240 Dogan
  2. Mikhail Roshal
    100 Roshal
  3. Carl Ola Landgren
    265 Landgren
  4. Qi   Gao
    23 Gao
  5. Maesa Toni Mae Bancod Koeber
    1 Koeber